As it happens, Bruker issued 9.5% more new shares over the last year. That means its earnings are split among a greater number of shares. Per share metrics like EPS help us understand how much ...

Publisher Focus Entertainment and developer Saber Interactive have announced Warhammer 40,000: Space Marine III. Platforms and a release window were not announced. “We’re pleased to announce ...

Includes reviews of Autoflex Leasing from DealerRater. Want to share your experience with this dealership? I have worked with Brian in the past and he is always top notch is making sure everything ...

Includes reviews of Autoflex Leasing from DealerRater. Want to share your experience with this dealership? I want to thank Daniel and Autoflex for you patience and hard work to help me with my new ...

Feb. 19 (UPI) --The U.S. Air Force demonstrated the nation's nuclear readiness by launching an unarmed Minuteman III intercontinental ballistic missile from Vandenberg Space Force Base in ...

In this article, we are going to take a look at where Bruker Corporation (NASDAQ:BRKR) stands against the other medical technology stocks. The MedTech sector is crucial in healthcare, which ...

The new series “Eyes on the Prize III,” which covers the civil rights movement from 1977 to 2015, has been in development for many years. The fact that it arrives on HBO Tuesday, in the midst ...

The Minuteman III intercontinental ballistic missile was launched from the Santa Barbara County base around 1 a.m. Wednesday. The goal is to “demonstrate the readiness of U.S. nuclear forces and ...

The U.S. Air Force Global Strike Command told Newsweek that the Minuteman III ICBM fleet is "extremely reliable" and remains "safe, secure, effective, and credible." The Russian Defense Ministry ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and ...